The stock last traded at $29.03 slightly over $27.44, the 50 day moving average and which is a tad above the 200 day moving average of $24.28. The 50 day moving average was up $1.59 and the 200 day average went up $4.75 or +19.57%. 825K shares changed hands in the last trading session. Shares saw a steep increase in trading volume of 20.09% over the normal average daily volume.
Traders are more bearish on shares of the company lately if you consider the change in short interest. The stock had a rise in short interest of 12.20% as of the latest report on May 31, 2017. Short interest grew from 2,704,919 to 3,034,785 over that timeframe. With short interest at 3,034,785 and short average daily volume at 743,014, days to cover is 4.1 and the short interest percentage is 0.02% as of May 31.
Bruker Corporation (NASDAQ:BRKR) has been the object of insider buying and selling activity recently. Ingen Chris Van, Director let go of $557,797 worth of shares at an average price of $28.03 on Wed the 14th. The Director now owns $128,293 of the stock as recorded in a recent Form 4 SEC filing. Exec VP Mark Munch disclosed the sale of 73,724 shares of BRKR stock. The shares were purchased at an average price of $27.62. Munch now owns $1,696,559 of the stock per the Form 4 SEC filing.
CEO Frank H. Laukien purchased 3,200 shares at an average price of $26.13 on Fri the 19th. That brings the CEO’s holdings to $987,427,903 as reported to the SEC.
These funds have also shifted positions in (BRKR). As of quarter end Clinton Group Inc had disposed of a total of 15,784 shares trimming its stake by 44.4%. The value of the company’s investment in Bruker Corporation decreased from $753,000 to $461,000 a change of $292,000 for the reporting period. Gw&k Investment Management, LLC cut its investment by shedding 2,532 shares a decrease of 2.9% as of 06/30/2017. Gw&k Investment Management, LLC owns 84,359 shares with a value of $2,433,000. The value of the position overall is up by 20.0%.
Piedmont Investment Advisors LLC grew its stake by buying 20,665 shares an increase of 131.2% from 12/31/2016 to 03/31/2017. Piedmont Investment Advisors LLC claims 36,420 shares valued at $850,000. The total value of its holdings increased 155.3%. As of the end of the quarter Tower Research Capital LLC (trc) had bought 341 shares growing its holdings by 277.2%. The value of the investment in BRKR went from $3,000 to $11,000 a change of 266.7% quarter to quarter.
On July 13 the company was changed to a “Underperform” in a report from Wells Fargo which is down from the previous “Outperform” rating. On December 14 the stock rating was downgraded to “Underweight” from “Neutral” with a current price target of $20.00 in a report from JP Morgan.
On December 14, 2016 JP Morgan held the price target at $20.00 and downgraded the stock from Neutral to Underweight. Leerink Swann started coverage by announcing an initial rating of “Market Perform”.
On July 22, 2016 BTIG Research starting coverage on BRKR with an initial rating of “Neutral”. On May 5, 2016 the stock rating was rated “Neutral” by BTIG Research which was a cut from the previous “” rating.
The company is down by -0.03% since yesterday’s close of $29.04. The company declared a dividend paid on Friday the 23rd of June 2017. The dividend was $0.040 per share for the quarter or $0.16 annualized. The dividend yield was $0.55. The ex-dividend date was set for Thursday the 1st of June 2017.
The most current P/E ratio is 30.82 and the market cap is 4.64B. As of the last earnings report the EPS was $0.94 and is expected to be $1.10 for the current year with 159,768,000 shares now outstanding. Analysts expect next quarter’s EPS to be $0.27 with next year’s EPS projected to be $1.24.
Bruker Corporation, launched on February 4, 2000, is a developer, manufacturer and distributor of scientific instruments and analytical and diagnostic solutions that enable its customers to explore life and materials at microscopic, molecular and cellular levels. The Business’s segments include Bruker Scientific Instruments (BSI) and Bruker Energy & Supercon Technologies (BEST). The Business’s products address the evolving needs of an array of customers in life science research, pharmaceuticals, biotechnology, applied markets, cell biology, clinical research, microbiology, in-vitro diagnostics, nanotechnology and materials science research. Its technology platforms include magnetic resonance technologies, mass spectrometry technologies, gas and liquid chromatography triple quadrupole mass spectrometry technologies, X-ray technologies, spark-optical emission spectroscopy, atomic force microscopy, stylus and optical metrology technology, fluorescence optical microscopy and infrared and Raman molecular spectroscopy technologies. It also develops, manufactures and distributes a range of field analytical systems for chemical, biological, radiological, nuclear and explosives (CBRNE) detection. It also develops, manufactures and markets high and low temperature superconducting materials and devices based primarily on metallic low temperature superconductors..